Enterome to Attend Jefferies Global Healthcare Conference

Enterome, a biopharmaceutical company in the clinical stage of development, specializes in creating innovative immunomodulatory drugs for various cancers and inflammatory conditions. These treatments are grounded in Enterome's unique Mimicry platform, which explores the interactions between human biology and millions of gut bacterial proteins. This approach has led to the discovery of novel biological insights critical for drug development.

Enterome's focus includes the creation of small protein and peptide drug candidates designed to modulate the immune system. These candidates function by mimicking the structure and actions of specific antigens, hormones, or cytokines, thereby triggering desired immune responses.

The company's pipeline features two main categories of drug candidates. The OncoMimics™ series targets cancer with peptide-based immunotherapies. Among these, EO2463 is in a Phase 2 clinical trial for treating indolent non-Hodgkin lymphomas and has shown a promising safety profile with early efficacy indicators. Another candidate, EO2401, completed its Phase 2 clinical trial for glioblastoma. Enterome is currently seeking a pharmaceutical partner to progress EO2401 into a pivotal trial phase.

The second category is EndoMimics™, which includes bioactive therapeutic proteins designed to replicate the effects of human hormones or cytokines. These are being developed in collaboration with Nestlé Health Science and target conditions such as food allergies and inflammatory bowel disease (IBD).

Enterome, headquartered in Paris, France, employs 70 people. Since its founding, the company has secured €118 million from investors in Europe and the US, along with over €100 million from pharmaceutical collaborations.

Enterome's leadership team, including co-founder and CEO Pierre Bélichard and CFO Christelle Dumoussaud, will attend the Jefferies Global Healthcare Conference at the Marriott Marquis in New York from June 4-6, 2024. This event is an opportunity for the company to highlight its progress and connect with potential partners and investors.

In summary, Enterome stands out for its innovative use of bacterial Mimicry in drug discovery, focusing on creating first-in-class therapeutics for challenging medical conditions like cancer and immune diseases. The company continues to advance its pipeline through strategic partnerships and clinical trials, underscoring its commitment to developing groundbreaking medical treatments.